Lupin launches generic Niaspan tablets in US market

Mumbai-based pharma major Lupin Ltd today launched its generic version of Niaspan extended release tablets, used in reducing cholesterol in the US market.

The company's US subsidiary, Lupin Pharmaceuticals Inc has launched the generic Niaspan tablets in multiple strengths of 500mg, 750 mg & 1000 mg having received final approval from the US Food and Drug Administration (USFDA), Lupin said in a statement.

These tablets are generic equivalent of AbbVie Inc's Niaspan tablets.

Commenting on the launch, Lupin Ltd Managing Director Nilesh Gupta said: "We are happy to launch this product having received approval from the (US) FDA yesterday. The launch bears testimony to our commitment to serving our customers and patients by bringing high quality, affordable medicines to the market."

Citing IMS MAT data, the company said Niaspan Tablets had annual sales of of approximately USD 1 billion in the US in 2013.

Niaspan tablets are used with diet to lower bad cholesterol while increasing the levels of good cholesterol in the body.

Lupin Ltd shares gained 0.45 per cent on the BSE from the previous close, ending the day at Rs 944.2 per scrip.

EDITORIAL OF THE DAY

  • Allow 100 per cent FDI in asset reconstruction companies

    The asset reconstruction business is 13 years old and still struggling like a toddler.

FC NEWSLETTER

Stay informed on our latest news!

INTERVIEWS

Sarthak Raychaudhuri

vice-president, HR, Asia South Whirlpool of India

GV Nageswara Rao

MD & CEO, IDBI Federal Life

Timothy Moe

Goldman Sachs

TODAY'S COLUMNS

Arun Nigavekar

Moocs will not replace traditional education

I am revisiting the topic of massive open online course ...

Rajgopal Nidamboor

From complexity to prudent adaptability

It is a travesty that a host of new, strikingly ...

Dharmendra Khandal

Creepy, you say? That’s merely ophidiphobia

Snakes are the earliest predators in the life of the ...

INTERVIEWS

William D. Green

Chairman & CEO, Accenture